Diagnosis & Disease Information

First-line treatment with serplulimab plus chemotherapy improves survival over chemotherapy alone in patients with advanced squamous NSCLC, a phase 3 trial suggests.

Iruplinalkib, a novel ALK inhibitor, was more effective than crizotinib in a phase 3 trial of patients with advanced, ALK-positive non-small cell lung cancer.

Researchers have found evidence to suggest that patients with metastatic non-small cell lung cancer have unique gut microbiomes.

Neoadjuvant camrelizumab in combination with either platinum-doublet chemotherapy or apatinib has demonstrated efficacy in stage II-III NSCLC, according to researchers.

Adding tumor-treating fields therapy to standard treatment improves survival in patients with metastatic non-small cell lung cancer, a study suggests.